The DOI matches its Crossref record.
Rituximab treatment of the anti-synthetase syndrome—a retrospective case series
Abstract
OBJECTIVE: Interstitial lung disease (ILD) is the major determinant of morbidity and mortality in the anti-synthetase syndrome (ASS). Here we have retrospectively assessed 11 ASS patients with ILD treated with the anti-CD20 mAB rituximab at our tertiary referral hospital. METHODS: Data on clinical and laboratory parameters, lung imaging by high-resolution CT thorax and pulmonary function tests were collected from patient examinations done up to 6 months before rituximab was initiated, and at 3 and 6 months post-treatment. RESULTS: All the 11 ASS patients had severe and progressive ILD and most of them had previously failed on cyclophosphamide and/or other immuno-modulating agents. Rituximab appeared to stabilize and/or improve the ILD in 7 of 11 ASS patients during the first 6 months after treatment. The rituximab treatment appeared to decrease the serum level of anti-Jo-1 antibodies, but the decrease was most often modest. One patient developed a fatal infection 3 months after the last infusion with rituximab. In the other ASS patients, the treatment was well tolerated. CONCLUSIONS: This retrospective case series indicates a short-term beneficial effect of rituximab in ASS. Prospective, controlled studies are needed to validate this finding and further assess safety issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Doença pulmonar intersticial relacionada a miosite e a síndrome antissintetase
Solomon, J., Swigris, J. J., & Brown, K. K. (2011) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132011000100015 · Cited by 335
An overview of polymyositis and dermatomyositis
Findlay, A. R., Goyal, N. A., & Mozaffar, T. (2015) · Muscle & Nerve · doi:10.1002/mus.24566 · Cited by 259
Rituximab in severe, treatment-refractory interstitial lung disease
Keir, G. J., Maher, T. M., Ming, D., Abdullah, R., de Lauretis, A., Wickremasinghe, M., Nicholson, A. G., Hansell, D. M., Wells, A. U., & Renzoni, E. A. (2014) · Respirology · doi:10.1111/resp.12214 · Cited by 256
The Diagnosis and Treatment of Antisynthetase Syndrome
Witt, L. J., Curran, J. J., & Strek, M. E. (2016) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000171 · Cited by 253
Kahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190
Metadata
- Authors
- Sem, M., Molberg, Ø., Lund, M. B., & Gran, J. T.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-06-16
- Volume
- 48
- Issue
- 8
- Pages
- 968-971
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2127075206
- Cited by
- 218
- References
- 0
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab treatment of the anti-synthetase syndrome—a retrospective case series. https://app.cochat.ai/papers/10.1093/rheumatology/kep157
- The paper
- Sem, M., Molberg, Ø., Lund, M. B., & Gran, J. T. (2009). Rituximab treatment of the anti-synthetase syndrome—a retrospective case series. Rheumatology. https://doi.org/10.1093/rheumatology/kep157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.